The firm has multiple catalysts that could generate a rally of 35% for the stock.
Arbutus Biopharma and Genevant have expanded their patent infringement actions against Pfizer and BioNTech by adding new ...
On the oncology side, BioNTech has agreed to buy an FDA Priority Review Voucher from Scholar Rock for $205 million in cash.
BioNTech also raised the lower bound of its full-year 2026 revenue guidance, now expecting a range of €1.7 billion to €1.9 ...
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) ...
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BioNTech (BNTX) ADRs lost ~5% in the premarket on Thursday after Bloomberg News reported that Pfizer (PFE) is planning to sell its remaining stake in its partner, which helped the U.S. pharma giant to ...
Add Yahoo as a preferred source to see more of our stories on Google. Pfizer Inc. signage is seen on July 22, 2020 in New York City. Pfizer and partner BioNTech said they will halt a ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...
COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies. BioNTech is the Marketing Authorization Holder for COMIRNATY® and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results